TRBG · Turbogen Ltd.

TurboGen Ltd. is a pre-commercial Israeli clean-energy technology company developing multi-fuel microturbines for localized combined heat and power generation in urban buildings. Founded in 2014, it operates exclusively in the development stage—having installed demonstration units and secured pilot agreements—but has yet to generate any revenue. Its core value proposition centers on modular, hydrogen-capable microturbines (e.g., TG-40, TR3200) designed for cost-efficient, resilient, low-carbon energy supply in markets with advanced natural gas infrastructure, primarily the U.S. and EU. The company’s business model relies heavily on an Energy-as-a-Service (EaaS) framework, where customers pay for energy output rather than upfront hardware, reducing adoption barriers but deferring monetization. While it has signed non-binding letters of intent with entities like CSA 8411 LLC and Sunflower GmbH, and binding agreements with ENPG and a multinational defense subsidiary, none have yielded revenue to date. Financially, TurboGen is deeply unprofitable and cash-constrained: it reported a $19.5 million net loss for 2025 and held just $3.9 million in cash as of year-end, while carrying $9.8 million in current liabilities—including an $8.3 million warrants liability. Its balance sheet reflects a working capital deficit of $3.2 million and accumulated deficits totaling $43.5 million, prompting its auditor to issue a going concern qualification. This offering is not a capital raise for TurboGen itself—it is a resale registration for 3.06 million Ordinary Shares held by selling shareholders, including major investors like Alex Katz and Ofer Eytan. TurboGen will receive no proceeds from these resales, though it expects to collect cash from future warrant exercises, which it intends to use for general corporate purposes and working capital. The company’s path to viability hinges on successful commercialization of its microturbines, scaling production via European suppliers, and navigating complex dependencies—including licensing restrictions from Rafael that require explicit consent for military or dual-use adaptations, exposing it to delays or strategic constraints. Governance is concentrated: Anglo Turbo and Emil Katan control 33% of voting power, and the board includes multiple directors affiliated with controlling shareholders. As a foreign private issuer and emerging growth company, TurboGen benefits from reduced disclosure obligations, but also faces heightened investor uncertainty around financial transparency, regulatory compliance, and enforceability of U.S. securities claims in Israel. Given its pre-revenue status, material going concern risk, and reliance on uncertain milestones—including Nasdaq listing approval and milestone-based warrant conversions—the offering represents a critical step toward U.S. market access but carries substantial execution and valuation risk for prospective investors.